TY - JOUR
T1 - Chest wall resection for non-small cell lung cancer
T2 - A case-matched study of postoperative pulmonary function and quality of life
AU - Liu, Ming
AU - Wampfler, Jason A.
AU - Dai, Jie
AU - Gupta, Ruchi
AU - Xue, Zhiqiang
AU - Stoddard, Shawn M.
AU - Cassivi, Stephen D.
AU - Jiang, Gening
AU - Yang, Ping
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background To assess the pulmonary function and quality of life (QOL) after chest wall resection for non-small cell lung cancer. Material and methods One hundred and thirty-five patients (cases) who underwent pulmonary resection with chest wall removal were identified from January 1997 to December 2015. Propensity score matching (1:3) was applied to balance known confounders for pulmonary function and QOL between the cases and the control group who underwent pulmonary resection without chest wall invasion. Matched analyses were performed to compare perioperative mortality and morbidity, postoperative pulmonary function, overall QOL, and specific symptoms. Results Perioperative mortality and morbidity did not differ significantly between cases and controls, but the hospital stay was longer in cases than in controls (mean, 12.8 vs 8.9 days; p < 0.001), The decline of postoperative pulmonary forced vital capacity (FVC) and the percentage of predicted FVC (FVC%) was more obvious in cases than in controls at 6 months and 2 years after surgery, but there was no obvious decline in the forced expiratory volume in one second (FEV1), the percentage of predicted FEV1 (FEV1%), the diffusion capacity of the lung for carbon monoxide (DLCO) and the percentage of predicted DLCO (DLCO%) in cases compared with controls. No significant difference was observed between the two groups in scores for overall QOL, pain, fatigue, cough, dyspnea, appetite, hemoptysis, lung cancer symptoms, and normal activities. Conclusions When chest wall resection is inevitable, it does not worse the QOL and pulmonary function of patients who underwent pulmonary resection with chest wall removal obviously compared with patients underwent pulmonary resection without chest wall invasion.
AB - Background To assess the pulmonary function and quality of life (QOL) after chest wall resection for non-small cell lung cancer. Material and methods One hundred and thirty-five patients (cases) who underwent pulmonary resection with chest wall removal were identified from January 1997 to December 2015. Propensity score matching (1:3) was applied to balance known confounders for pulmonary function and QOL between the cases and the control group who underwent pulmonary resection without chest wall invasion. Matched analyses were performed to compare perioperative mortality and morbidity, postoperative pulmonary function, overall QOL, and specific symptoms. Results Perioperative mortality and morbidity did not differ significantly between cases and controls, but the hospital stay was longer in cases than in controls (mean, 12.8 vs 8.9 days; p < 0.001), The decline of postoperative pulmonary forced vital capacity (FVC) and the percentage of predicted FVC (FVC%) was more obvious in cases than in controls at 6 months and 2 years after surgery, but there was no obvious decline in the forced expiratory volume in one second (FEV1), the percentage of predicted FEV1 (FEV1%), the diffusion capacity of the lung for carbon monoxide (DLCO) and the percentage of predicted DLCO (DLCO%) in cases compared with controls. No significant difference was observed between the two groups in scores for overall QOL, pain, fatigue, cough, dyspnea, appetite, hemoptysis, lung cancer symptoms, and normal activities. Conclusions When chest wall resection is inevitable, it does not worse the QOL and pulmonary function of patients who underwent pulmonary resection with chest wall removal obviously compared with patients underwent pulmonary resection without chest wall invasion.
KW - Chest wall resection
KW - Non-small cell lung cancer
KW - Pulmonary function test
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85011556710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011556710&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2017.01.014
DO - 10.1016/j.lungcan.2017.01.014
M3 - Article
C2 - 28285692
AN - SCOPUS:85011556710
SN - 0169-5002
VL - 106
SP - 37
EP - 41
JO - Lung Cancer
JF - Lung Cancer
ER -